Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Tablets: SOP for Compliance with cGMP Guidelines in Tablet Production – V 2.0

Posted on By

Tablets: SOP for Compliance with cGMP Guidelines in Tablet Production – V 2.0

Standard Operating Procedure for Compliance with cGMP Guidelines in Tablet Production

Department Tablet
SOP No. SOP/TAB/179/2025
Supersedes SOP/TAB/179/2022
Page No. Page 1 of 6
Issue Date 01/03/2026
Effective Date 06/03/2026
Review Date 01/03/2027

1. Purpose

To define the procedures for ensuring compliance with current Good Manufacturing Practice (cGMP) guidelines in tablet production, ensuring the production of safe, effective, and high-quality tablets.

2. Scope

This SOP applies to all aspects of tablet production, including raw material handling, formulation, tablet compression, coating, packaging, and final product inspection, ensuring that all activities meet cGMP standards.

3. Responsibilities

  • Quality Assurance (QA): Responsible for overseeing compliance with cGMP guidelines, performing audits, and reviewing documents related to production processes.
  • Production Supervisors: Ensure that all production activities follow established cGMP guidelines and SOPs, and that employees are properly trained in cGMP procedures.
  • Maintenance Team: Responsible for ensuring that equipment is properly calibrated, maintained, and functioning according to cGMP standards.
  • All Personnel: Follow all cGMP guidelines, report deviations or non-compliance, and ensure that personal hygiene and protective clothing requirements are met.

4. Accountability

The QA Manager is accountable for ensuring that the tablet production process adheres to cGMP

guidelines and that all records and documentation are maintained in compliance with regulatory requirements.

5. Procedure

5.1 Training and Awareness

  1. Ensure that all personnel involved in tablet production receive initial and periodic training on cGMP guidelines, company policies, and specific SOPs related to their roles.
  2. Training should include cGMP requirements for raw material handling, equipment operation, sanitation practices, documentation, and safety protocols.
  3. Keep records of all training sessions, including attendee names, training dates, and materials covered (Annexure-1).
See also  Tablets: SOP for Cleaning Checks Between Granulation Batches - V 2.0

5.2 Documentation and Record Keeping

  1. Ensure that all production activities are documented, including batch records, cleaning logs, calibration logs, and any other records required by cGMP.
  2. Ensure that records are accurate, legible, and complete, and that they are retained for the required period as per regulatory guidelines (Annexure-2).
  3. Review and approve documents as necessary to ensure compliance with cGMP requirements before use in production.

5.3 Raw Material Control

  1. Verify that all raw materials used in tablet production are approved for use, stored, and handled in compliance with cGMP guidelines.
  2. Ensure that raw materials are received from approved vendors, and that Certificates of Analysis (CoA) are reviewed for each batch (Annexure-3).
  3. Maintain a system for tracking raw materials from receipt through production to final product release.

5.4 Equipment and Facility Control

  1. Ensure that all equipment used in tablet production is properly calibrated, maintained, and cleaned according to the required cGMP standards.
  2. Monitor environmental conditions in production areas, including temperature, humidity, and cleanliness, to meet cGMP specifications.
  3. Maintain and review records of equipment calibration and maintenance (Annexure-4).

5.5 In-Process Controls

  1. Implement in-process controls to monitor key production parameters such as weight variation, tablet hardness, dissolution, and coating thickness during tablet manufacturing.
  2. Use statistical process control methods to track variations and ensure that all in-process parameters remain within defined limits.
  3. Document all in-process control data and take corrective actions as necessary to ensure the product meets specifications (Annexure-5).

5.6 Final Product Testing

  1. Ensure that all final tablet products undergo testing for quality attributes, including but not limited to weight uniformity, hardness, dissolution, and friability, in compliance with cGMP standards.
  2. Review and approve all testing results before release, ensuring that they meet the required specifications.
  3. Document all final product test results and release forms (Annexure-6).
See also  Tablets: SOP for Temperature Adjustment During Film Coating Process - V 2.0

5.7 Sanitation and Hygiene

  1. Implement strict sanitation procedures for the tablet production area, including regular cleaning and disinfecting of equipment and surfaces to prevent contamination.
  2. Ensure that all personnel adhere to hygiene protocols, including wearing appropriate personal protective equipment (PPE), following handwashing protocols, and using cleanroom garments as required.
  3. Maintain records of cleaning and sanitization activities (Annexure-7).

5.8 Corrective and Preventive Actions (CAPA)

  1. Establish a CAPA process to investigate any deviations from cGMP guidelines or non-compliance issues that arise during tablet production.
  2. Implement corrective actions to address root causes and preventive actions to avoid recurrence of issues.
  3. Document all CAPA activities and monitor the effectiveness of the implemented actions (Annexure-8).

5.9 Internal Audits

  1. Conduct regular internal audits to ensure ongoing compliance with cGMP guidelines. Audits should cover all areas of tablet production, including raw material handling, equipment calibration, in-process controls, and documentation.
  2. Audit findings should be documented and corrective actions should be taken for any non-conformities.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • GMP: Good Manufacturing Practice
  • QA: Quality Assurance
  • QC: Quality Control
  • CAPA: Corrective and Preventive Action

7. Documents

  1. Training Records (Annexure-1)
  2. Production Records (Annexure-2)
  3. Certificate of Analysis (CoA) Records (Annexure-3)
  4. Equipment Maintenance and Calibration Logs (Annexure-4)
  5. In-Process Control Data (Annexure-5)
  6. Final Product Testing Records (Annexure-6)
  7. Cleaning and Sanitation Records (Annexure-7)
  8. CAPA Records (Annexure-8)

8. References

  • 21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals (US FDA)
  • ISO 9001 – Quality Management Systems
  • ICH Q7 – Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
See also  Tablets: SOP for Post-Coating Drying Process Validation - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Training Records

Employee Name Training Date Training Topic Trainer Name Score
John Doe 01/01/2026 cGMP Compliance Jane Smith 90%

Annexure-2: Production Records

Batch Number Production Date Material Used Quantity Produced Signature
Batch-12345 01/01/2026 Material A 5000 Tablets John Doe

Annexure-3: Certificate of Analysis (CoA) Records

Raw Material CoA Number Testing Date Test Results
Excipient A CoA-123 01/01/2026 Pass

Annexure-4: Equipment Maintenance and Calibration Logs

Equipment ID Calibration Date Next Calibration Date Maintenance Performed
Tablet Press-001 01/01/2026 01/01/2027 Recalibrated and serviced

Annexure-5: In-Process Control Data

Batch Number Test Parameter Specification Measured Value Corrective Action
Batch-12345 Tablet Hardness 15-25 N 20 N None

Annexure-6: Final Product Testing Records

Batch Number Test Parameter Specification Test Result Release Status
Batch-12345 Weight Uniformity ±5% Pass Released

Annexure-7: Cleaning and Sanitation Records

Area Cleaned Cleaning Date Cleaning Personnel Cleaning Agent Used
Compression Area 01/01/2026 Jane Smith Disinfectant A

Annexure-8: CAPA Records

CAPA ID Issue Description Corrective Action Preventive Action Completion Date
CAPA-001 Deviation in tablet hardness Adjusted compression force Reviewed process parameters 01/02/2026

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial Version New SOP Creation QA Head
01/02/2025 2.0 Updated documentation and CAPA procedures Improved clarity and compliance measures QA Head
Tablet Manufacturing V2.0 Tags:GMP tablet manufacturing SOP, SOP for tablet production, SOP for tablet quality control, SOP tablet inspection process, SOP tablet packing and sealing, Tablet batch record review, Tablet blending SOP, Tablet cleaning and maintenance, Tablet coating procedure, Tablet compression SOP, Tablet disintegration test procedure, Tablet dissolution procedure, Tablet formulation SOP, Tablet friability testing SOP, Tablet labeling and packaging SOP, Tablet manufacturing equipment SOP, Tablet manufacturing SOP, Tablet manufacturing SOPs, Tablet packaging SOP, Tablet production procedure, Tablet quality assurance SOP, Tablet quality control SOP, Tablet sampling and in-process testing SOP, Tablet stability testing SOP, Tablet storage and handling procedure, Tablet uniformity testing procedure, Tablet weight variation SOP

Post navigation

Previous Post: Capsule: SOP for Routine Cleaning of Airlocks in Capsule Manufacturing Areas – V 2.0
Next Post: Aerosol: SOP for Documenting In-Process Control Activities – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version